Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners cut their target price on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Stock Down 1.6 %

Shares of AWH opened at $0.90 on Friday. The business has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.61. The stock has a market cap of $14.46 million, a price-to-earnings ratio of -0.62 and a beta of 1.47. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $5.65.

Aspira Women’s Health (NASDAQ:AWH) last released its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $2.60 million. During the same quarter in the prior year, the business posted ($0.28) EPS. On average, equities analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.